Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Sylvestre R. M. Tiendrebéogo"'
Autor:
Olivier Ronveaux, Simona Zipursky, Laifoya Olodo, Mamoudou Harouna Djingarey, Sylvestre R. M. Tiendrebéogo, Jean-Claude Lodjo
Publikováno v:
Vaccine
Highlights • The first field use of MenAfriVac's new label allowed the vaccine to be kept at up to 40 °C for up to 4 days. • 155,000 people were vaccinated using the CTC approach in the Meningitis A campaign in northern Benin in 2012. • 98.7%
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed12a84043c8b0fad4f1410a57e262e2
https://doi.org/10.1016/j.vaccine.2014.01.038
https://doi.org/10.1016/j.vaccine.2014.01.038
Impact of the Serogroup A Meningococcal Conjugate Vaccine, MenAfriVac, on Carriage and Herd Immunity
Autor:
Absatou Ky Ba, Marie-Pierre Préziosi, Stacey W. Martin, Paul A. Kristiansen, Inger Marie Saga, Mamoudou Harouna Djingarey, Abdoul Salam Ouedraogo, Jennifer Dolan Thomas, Fabien Diomandé, Lassana Sangaré, Flavien Aké, Rasmata Ouédraogo, Sylvestre R. M. Tiendrebéogo, Thomas A. Clark, Denis Kandolo, Nancy E. Messonnier, Lara K. Misegades, F. Marc LaForce, Musa Hassan-King, Dominique A. Caugant, Idrissa Sanou
Publikováno v:
Clinical Infectious Diseases. 56:354-363
Background The conjugate vaccine against serogroup A Neisseria meningitidis (NmA), MenAfriVac, was first introduced in mass vaccination campaigns of 1-29-year-olds in Burkina Faso in 2010. It is not known whether MenAfriVac has an impact on NmA carri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::27465e02a5cbadb4bcd989c73d62726e
https://doi.org/10.1093/cid/cis892
https://doi.org/10.1093/cid/cis892
Autor:
Leonard W. Mayer, Stacey W. Martin, Tiga F. Tarbangdo, Ryan T. Novak, Fenella Avokey, Clement Lingani, Cynthia Hatcher, Lassana Sangaré, Sylvestre R. M. Tiendrebéogo, Jean Ludovic Kambou, F. Marc LaForce, Nancy E. Messonnier, Fabien Diomandé, Thomas A. Clark, Rasmata Ouédraogo-Traoré, Mamoudou Harouna Djingarey
Publikováno v:
The Lancet Infectious Diseases. 12:757-764
An affordable, highly immunogenic Neisseria meningitidis serogroup A meningococcal conjugate vaccine (PsA-TT) was licensed for use in sub-Saharan Africa in 2009. In 2010, Burkina Faso became the first country to implement a national prevention campai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::987046066136b83b4e6209ff502a6214
https://doi.org/10.1016/s1473-3099(12)70168-8
https://doi.org/10.1016/s1473-3099(12)70168-8
Autor:
Chantal Kambire, Patrick L.F. Zuber, Sylvestre R. M. Tiendrebéogo, André Yaméogo, Rasmata Ouédraogo, Mac W. Otten, M. Kader Kondé, K. Lisa Cairns
Publikováno v:
The Journal of Infectious Diseases. 187:S80-S85
Burkina Faso conducted mass measles vaccination campaigns among children aged 9 months to 4 years during December 1998 and December 1999. The 1998 campaign was limited to six cities and towns, while the 1999 campaign was nationwide. The last year of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba235019a4fbcc39ba672e63080069bf
https://doi.org/10.1086/368043
https://doi.org/10.1086/368043
Autor:
Desire Toboe, Clement Lingani, Stéphane Hugonnet, Nancy E. Messonier, Richard Mihigo, Denis Kandolo, Leonard W. Mayer, Patrick L.F. Zuber, William Perea, Mete Bonkoungou, F. Marc LaForce, Teresa Aguado, Nora Dellepiane de Rey Tolve, Carole Tevi-Benissan, Marie-Pierre Préziosi, Rodrigue Barry, Rene Sebgo, Mamoudou Harouna Djingarey, Fabien Diomandé, Dominique A. Caugant, Deo Nshimirimana, Monique Berlier, Thomas A. Clark, Sylvestre R. M. Tiendrebéogo, Ryan T. Novak, Paul A. Kristiansen
Publikováno v:
Vaccine. 30
A new Group A meningococcal (Men A) conjugate vaccine, MenAfriVac™, was prequalified by the World Health Organization (WHO) in June 2010. Because Burkina Faso has repeatedly suffered meningitis epidemics due to Group A Neisseria meningitidis specia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f015729a90ab8f0f6646334c861fd333
https://pubmed.ncbi.nlm.nih.gov/22607898
https://pubmed.ncbi.nlm.nih.gov/22607898
Autor:
Sylvestre R. M. Tiendrebéogo, J.-F. Aguilera, Berthe-Marie Njanpop-Lafourcade, P. Stoecke, R. T. Ouedraogo, W. Goehde, Yves Traoré, Judith E. Mueller, Bradford D. Gessner, Philippe Jaillard, M. Dabal, A. da Silva
Publikováno v:
Field Actions Science Reports (2009)
Field Actions Science Reports, Iss Vol. 1 (2009)
Field Actions Science Reports, Iss Vol. 1 (2009)
A Mobile Laboratory was developed for use primarily during the epidemic meningitis season in Burkina Faso. This report describes the Mobile Laboratory characteristics, its use to date, problems encountered and their resolution, and future directions.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc61db6e842f0d6884b4616361ebf2a9
http://journals.openedition.org/factsreports/144
http://journals.openedition.org/factsreports/144
Autor:
Christopher B. Nelson, Robert Pless, Issaka Zongo, Selma Khamassi, Philippe Duclos, Sylvestre R. M. Tiendrebéogo, Rigobert Thombiano, Adwoa D Bentsi-Enchill
Publikováno v:
Vaccine. 25
During a mass campaign with a newly licensed meningococcal polysaccharide ACW135 vaccine in Burkina Faso, adverse events following immunization (AEFI) were monitored up to 4 weeks after the campaign. Eighty-six AEFI cases (5.9 cases per 100,000 vacci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3cb4cfe43c1de4a8b73876fe46c1c968
https://pubmed.ncbi.nlm.nih.gov/17544552
https://pubmed.ncbi.nlm.nih.gov/17544552
Autor:
Sylvestre R. M. Tiendrebéogo, Peter Firmenich, Dominique Legros, Catherine Bachy, Philippe J Guerin, Dominique A. Caugant, Angela M. C. Rose, N. Nathan, Egil Bjørløw
Publikováno v:
Emerging Infectious Diseases
Emerging Infectious Diseases, Vol 13, Iss 6, Pp 920-920 (2007)
Emerging Infectious Diseases, Vol 13, Iss 6, Pp 920-920 (2007)
In 2002, the largest epidemic of Neisseria meningitidis serogroup W135 occurred in Burkina Faso. The highest attack rate was in children
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e733d7ddb74f37c15671572c0a3d85a6
http://ora.ox.ac.uk/objects/uuid:69c20dae-dee5-40ef-9513-6a054cc036fc
http://ora.ox.ac.uk/objects/uuid:69c20dae-dee5-40ef-9513-6a054cc036fc
Autor:
Montse Soriano-Gabarró, Christopher B. Nelson, Sylvestre R. M. Tiendrebéogo, Brian D. Plikaytis, Moumouni Dabal, Nancy E. Rosenstein, Mamoudou Harouna Djingarey, Laurent Toe
Publikováno v:
Vaccine. 25
Following a large Neisseria meningitidis W135 (NmW135) epidemic in Burkina Faso (BF) during 2002, a newly licensed trivalent A/C/W135 meningococcal polysaccharide vaccine was introduced in 2003. We conducted a case-control study to assess the vaccine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37fea49e4ab2d3f7d6fd1c89860eca1e
https://pubmed.ncbi.nlm.nih.gov/17517451
https://pubmed.ncbi.nlm.nih.gov/17517451
Autor:
Cheryl M. Elie, Kassim Sidibe, Moumouni Dabal, Leonard W. Mayer, Pratima L Raghunathan, M. Kader Kondé, Montse Soriano-Gabarró, Tanja Popovic, Clement Lingani, Mary D. Ari, Idrissa Sanou, Julie Chatt, Scott E. Johnson, Joseph Martinez, Joshua D. Jones, Brian D. Plikaytis, Mamoudou Harouna Djingarey, George M. Carlone, Susanna Schmink, Lassana Sangaré, Seni Kouanda, Sylvestre R. M. Tiendrebéogo, Nancy E. Rosenstein
Publikováno v:
The Journal of infectious diseases. 193(5)
Background. The African meningitis belt undergoes recurrent epidemics caused by Neisseria meningitidis serogroup A. During 2002, Burkina Faso documented the first large serogroup W-135 (NmW-135) meningococcal disease epidemic. To understand the emerg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ca2e1460d784b83ad112ea9074d2917
https://pubmed.ncbi.nlm.nih.gov/16453255
https://pubmed.ncbi.nlm.nih.gov/16453255